Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.
about
Exercise therapy for ankylosing spondylitisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesEffectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot studyTreatment of ankylosing spondylitis with TNF blockers: a meta-analysis.Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012.Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.Biological therapies for spondyloarthritis.Biologics in spondyloarthritis: TNFα inhibitors and other agents.Pharmacological therapy of spondyloarthritis.Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis: Evolving New Concepts of Bone Formation and Future Trends in Management.New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.Exploring the relationship between demographic and disease-related variables and perceived effect of health status on sexual activity in patients with axial spondyloarthritis: associations found only with non-disease variables.Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.[What is ascertained in the therapy of axial spondyloarthritis?].TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis.A comparison of telephone and paper self-completed questionnaires of main patient-related outcome measures in patients with ankylosing spondylitis and psoriatic arthritis.Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy.Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.
P2860
Q24193372-0DC5476E-6476-42F9-80B4-EA9F77BFDC21Q26777084-B20C59E4-4157-4503-BC50-BEB74A67ECB7Q30776497-2D49A65B-F540-4F3A-BFD1-8B05DD9A2894Q33993099-E16229FF-DAC4-43AA-A33E-728A5BEFA671Q34277511-7A5F004F-9C1E-4A25-8024-0CBA8301415FQ34728162-65ED71A8-FA4E-421B-830E-D22392B9EDA9Q35708834-7869BED0-9B25-4321-9D31-A9A4D4BD1B8FQ35996265-B6DF291F-BD99-487F-8DEC-DCCBB7232107Q36182303-6BCF15B8-B12F-495B-B9DC-9E1193E30626Q37612248-3E4ADD98-1399-46CE-A56E-E05DE06CCEA5Q38217223-2A1A3EED-5A4A-4CC2-AB08-F60EAA797AE6Q38522331-71BB0FB9-8E93-4832-B7B3-23C16A89302AQ38527552-993AD4FF-3FD6-4FF4-879C-6E4774F591D9Q38540408-26E37F81-82BF-4C12-9575-8DD760EE5D2EQ38737389-9BF5E51E-1398-43DF-B449-718C3CB70BC8Q38768900-D7E4509B-A966-4CE4-8F5D-B1B637FDD0E8Q38907786-A96CB775-960A-4CFF-9F16-AD8512665366Q38972623-B4F65C67-D996-4FCB-9522-1CD3E7133350Q40556448-D7B9F810-99DF-4A6D-8AE3-70C8060BE21EQ46057173-F19E8671-D8C7-4C41-BBAB-051CEBC78CE0Q48628994-2539DC65-540D-4D26-A404-F77B15E15A52Q50703858-6EB04E8C-CDDD-4E76-9C56-1620BF714090Q52341767-6B0752C3-0DED-4F48-B76B-F0A309A9E03EQ54243018-8A14FF64-3028-49C1-A44A-FC90EF18E52A
P2860
Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Update of the literature revie ...... ons of ankylosing spondylitis.
@en
Update of the literature revie ...... ons of ankylosing spondylitis.
@nl
type
label
Update of the literature revie ...... ons of ankylosing spondylitis.
@en
Update of the literature revie ...... ons of ankylosing spondylitis.
@nl
prefLabel
Update of the literature revie ...... ons of ankylosing spondylitis.
@en
Update of the literature revie ...... ons of ankylosing spondylitis.
@nl
P2093
P2860
P356
P1433
P1476
Update of the literature revie ...... ons of ankylosing spondylitis.
@en
P2093
Jürgen Braun
Rosaline van den Berg
Xenofon Baraliakos
P2860
P304
P356
10.1093/RHEUMATOLOGY/KES026
P577
2012-03-16T00:00:00Z